Medicus Pharma Ltd. filed a Form 425 (filed as a current report under Item 7.01 Regulation FD Disclosure) on November 4, 2026, announcing a non-binding letter of intent for a potential business combination involving its wholly-owned subsidiary, Skinject, Inc., and an undisclosed special purpose acquisition company.

Key Highlights

  • Non-binding letter of intent: Medicus Pharma disclosed a non-binding letter of intent related to a potential business combination of its wholly-owned subsidiary, Skinject, Inc., with an undisclosed SPAC.
  • SPAC identity undisclosed: According to the filing, the special purpose acquisition company involved in the potential transaction has not been identified publicly.
  • Anticipated completion timeline: The filing states the anticipated completion of the proposed business combination is targeted during the first half of 2027, though there is no guarantee it will occur.
  • Majority ownership intention: The filing references Medicus' intention to retain majority economic and voting ownership of the combined company.
  • Potential regulatory filings: The filing notes that if definitive documentation is entered into, it is anticipated that a registration statement on Form S-4 and a proxy statement/prospectus will be filed with the SEC.
  • Exchange listing: Medicus Pharma common shares and warrants are listed on NASDAQ:MDCX and NASDAQ:MDCXW, respectively, on the NASDAQ Capital Market.

Medicus Pharma Discloses Skinject SPAC Letter of Intent Under Regulation FD

On November 4, 2026, Medicus Pharma Ltd. issued a press release, disclosed under Item 7.01 Regulation FD Disclosure, announcing that it had entered into a non-binding letter of intent in connection with a potential business combination. According to the filing, the transaction would involve Skinject, Inc., the company's wholly-owned subsidiary, and an undisclosed special purpose acquisition company. The filing notes that two press releases related to the proposed business combination and related matters were furnished as Exhibits 99.1 and 99.2.

The filing describes several forward-looking elements associated with the potential transaction, including the contemplated valuation of SkinJect, a proposed concurrent equity financing, and the anticipated capitalization and ownership structure of the combined company. Medicus disclosed its intention to retain majority economic and voting ownership of the combined company. The filing also references the planned initiation of the SKNJCT-005 registrational study in patients with Gorlin Syndrome, and states that the Company has decided to develop SkinJect exclusively for patients with Gorlin Syndrome.

Beyond the Skinject transaction, the filing's forward-looking statements section references Medicus' development programs, including Teverelix for advanced prostate cancer and women's health indications such as endometriosis, and a co-development arrangement with Pfizer related to CD228V across indications including melanoma, squamous non-small cell lung cancer, head and neck squamous cell carcinoma, and esophageal cancer. The company cautioned that all forward-looking statements are subject to risks and uncertainties described in its annual report on Form 10-K for the year ended December 31, 2025, and other public filings.

What Was Disclosed

Medicus Pharma Ltd. disclosed a non-binding letter of intent for a potential business combination of its subsidiary Skinject, Inc. with an unnamed SPAC, with anticipated completion in the first half of 2027. No definitive agreement has been signed, and regulatory filings would follow if one is reached.